Trial Profile
A Phase II/III, randomized, controlled, single blind study to evaluate the haemostatic efficacy and safety of topically applied TT-173 in patients undergoing knee arthroplasty
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs TT 173 (Primary)
- Indications Postoperative haemorrhage
- Focus Adverse reactions; Therapeutic Use
- Acronyms HESTAT
- Sponsors Thrombotargets Corporation
- 20 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
- 20 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 01 Oct 2017 Trial design published in the Contemporary Clinical Trials